ERBB2 and neoplasm: Although some early clinical trials have demonstrated the potential of combination therapy with ADCs and ICIs in cancers such as HER-2-positive breast cancer and non-small-cell lung cancer, the inconsistency of effects between different tumor types, as well as the potential for serious adverse events, highlight the need for further optimization of treatment regimens.